'Not colonial' Sanofi initiates KiDS in India
This article was originally published in Scrip
Sanofi is not a colonial company, said CEO Christopher Viehbacher at a media briefing in Mumbai on 30 September 2013. Addressing both the technology transfer agenda and Indian sensitivities to multinationals that appear to act in an imperialist fashion, it is not a firm that simply discovers and produces medicines in its home country and essentially looks for export markets, said Mr Viehbacher.
You may also be interested in...
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.